|
The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptomsKeywords: Nasal allergen, Nasal secretion, IL-13, IL-31, Kinetics Abstract: Seven seasonal allergic volunteers underwent unilateral nasal provocation with allergen (and a control challenge) with the disc method out of the allergy season. Nasal symptom scores (rhinorrhea, itching, sneezing, obstruction) and bilateral nasal secretions were quantified before and after allergen provocation. IL-13 and IL-31 in nasal secretions and serum were measured by electrochemiluminescent immunoassay or ELISA, respectively.Nasal allergen challenge induced the typical clinical symptoms and physiological changes. IL-31 and IL-13 in nasal secretions increased in four and five, respectively, volunteers at 5 h after allergen but not after control challenge. We observed correlation trends between nasal IL-31 concentrations and IL-13 concentrations (r?=?0.9, p?=?0.002), and IL-31 contents and symptom scores (r?=?0.9, p?=?0.013) 5 h after allergen provocation. No IL-31 could be detected contralaterally or systemically in the sera.The observed local upregulation of IL-31 mainly during the late phase reaction after nasal allergen challenge suggests a role of IL-31 in allergic rhinitis. In which way IL-31 modulates the inflammatory reaction and type 2 responses in allergic rhinitis remains to be investigated.IL-31 is a recently discovered member of the gp130/IL-6 cytokine family, which includes IL-6, IL-11, IL-27, oncostatin M (OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor, neuropoietin, cardiotrophin-1, and cardiotrophin-like cytokine [1,2]. IL-31 signals through a heterodimeric receptor composed of the IL-31 receptor alpha (IL-31RA) and the OSM receptor beta (OSMR). IL-31RA has been identified as a gp130-like receptor showing 28% homology to gp130, the common signalling receptor subunit of the family of IL-6-type cytokines [3-5].IL-31 is expressed by human mast cells [6] and by CD4+ T cells, particularly activated T helper type 2 (TH2) cells [1], and skin-homing CD45RO+ cutaneous lymphocyte-associated antigen-positive T cells [7]. IL-31 recepto
|